Anixa Biosciences (ANIX)
(Real Time Quote from BATS)
$3.09 USD
-0.14 (-4.33%)
Updated Apr 29, 2024 01:12 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for ANIXA BIOSCIENCES INC falls in the month of October .
All items in Millions except EPS data.
10/31/23 | 10/31/22 | 10/31/21 | 10/31/20 | 10/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 1 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 11 | 14 | 14 | 10 | 12 |
Income After Depreciation & Amortization | -11 | -14 | -13 | -10 | -12 |
Non-Operating Income | 1 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -10 | -14 | -13 | -10 | -12 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -10 | -14 | -13 | -10 | -12 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -10 | -14 | -13 | -10 | -12 |
Depreciation Footnote | 10/31/23 | 10/31/22 | 10/31/21 | 10/31/20 | 10/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -11 | -14 | -13 | -10 | -11 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -11 | -14 | -13 | -10 | -12 |
Earnings Per Share Data | 10/31/23 | 10/31/22 | 10/31/21 | 10/31/20 | 10/31/19 |
---|---|---|---|---|---|
Average Shares | 30.98 | 30.37 | 28.58 | 22.23 | 19.79 |
Diluted EPS Before Non-Recurring Items | -0.32 | -0.45 | -0.45 | -0.45 | -0.59 |
Diluted Net EPS (GAAP) | -0.32 | -0.45 | -0.45 | -0.45 | -0.59 |
Fiscal Year end for ANIXA BIOSCIENCES INC falls in the month of October .
All items in Millions except EPS data.
1/31/24 | 10/31/23 | 7/31/23 | 4/30/23 | 1/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.21 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.21 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 3.61 | 3.06 | 2.85 | 2.77 | 2.56 |
Income After SG&A, R&D, and Dept/Amort Expenses | -3.61 | -3.06 | -2.85 | -2.56 | -2.56 |
Non-Operating Income | 0.32 | 0.33 | 0.30 | 0.25 | 0.20 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -3.29 | -2.72 | -2.55 | -2.31 | -2.35 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | -0.04 | -0.03 | -0.04 | -0.02 | -0.03 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -3.29 | -2.72 | -2.55 | -2.31 | -2.35 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -3.26 | -2.69 | -2.51 | -2.29 | -2.32 |
Earnings Per Share Data | 1/31/24 | 10/31/23 | 7/31/23 | 4/30/23 | 1/31/23 |
---|---|---|---|---|---|
Average Shares | 31.45 | 29.89 | 30.97 | 30.93 | 30.92 |
Diluted EPS Before Non-Recurring Items | -0.10 | -0.09 | -0.08 | -0.07 | -0.08 |
Diluted Net EPS (GAAP) | -0.10 | -0.09 | -0.08 | -0.07 | -0.08 |